Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

International journal of endocrinology Том 16, №1, 2020

Back to issue

Obesity and Alzheimer’s disease

Authors: N.V. Pashkovska(1), V.I. Pankiv(2), O.V. Pashkovska(3)
(1) — Bukovinian State Medical University of the Ministry of Health of Ukraine, Chernivtsi, Ukraine
(2) — Ukrainian Research and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
(3) — Charles University in Prague, Prague, the Czech Republic

Categories: Endocrinology

Sections: Specialist manual

print version


Summary

В оглядовій статті наведені сучасні відомості щодо епідеміології i чинників ризику хвороби Альцгеймера при ожирінні. Проаналізовано дані літератури щодо основних патогенетичних ланок розвитку нейродегенеративних порушень у пацієнтів із ожирінням i метаболічним синдромом, а також механізмів взаємообтяження. Наведені результати клінічних та експериментальних досліджень щодо можливостей патогенетичної корекції когнітивних порушень при хворобі Альцгеймера, яка перебігає на тлі ожиріння, зазначені найбільш перспективні напрямки наукових досліджень із цієї проблеми.

В обзорной статье приведены современные сведения об эпидемиологии и факторах риска болезни Альцгеймера при ожирении. Проанализированы данные литературы по основным патогенетическим звеньям развития нейродегенеративных нарушений у пациентов с ожирением и метаболическим синдромом, а также механизмам взаимоотягощения. Представлены результаты клинических и экспериментальных исследований относительно возможностей патогенетической коррекции когнитивных нарушений при болезни Альцгеймера, которая протекает на фоне ожирения, указаны наиболее перспективные направления научных исследований по данной проблеме.

The article reviews modern information on epidemiology and risk factors for Alzheimer’s disease in obesity. The literature data on the main pathogenetic links of the development of neurodegenerative disorders in patients with obesity and metabolic syndrome are analyzed, as well as the mechanisms of mutual burden. The article deals with the results of clinical studies on the possibilities of pathogenetic correction of cognitive disorders in Alzheimer’s disease, which runs on the background of obesity.


Keywords

ожиріння; метаболічний синдром; хвороба Альцгеймера; когнітивні порушення

ожирение; метаболический синдром; болезнь Альцгеймера; когнитивные нарушения

obesity; metabolic syndrome; Alzheimer’s disease; cognitive disorders


For the full article you need to subscribe to the magazine.


Bibliography

1. World Population Review. Most Obese Countries 2020. http://worldpopulationreview.com/countries/most-obese-countries/. Available from: Feb 3, 2020.

2. Blüher M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019. 15. 288-298. https://doi.org/10.1038/s41574-019-0176-8.

3. Collaboration NC; NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017. 390(10113). 2627-42.

4. World Health Organization. Dementia. http://www. who.int/mediacentre/factsheets/fs362/en/. Available from: Feb 3, 2020.

5. Lane C.A., Hardy J., Schott J.M. Alzheimer’s disease. Eur. J. Neurol. 2018. 25(1). 59-70. doi: 10.1111/ene.13439.

6. Barron A.M., Rosario E.R., Elteriefi R., Pike C.J. Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: implications for Alzheimer’s disease. PLoS One. 2013. 8(10). e78554. doi: 10.1371/journal.pone.0078554.

7. Julien C., Tremblay C., Phivilay A. et al. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging. 2010. 31(9). 1516-31. doi: 10.1016/j.neurobiolaging.2008.08.022.

8. Knight E.M., Martins I.V., Gümüsgöz S., Allan S.M., Lawrence C.B. High-fat diet-induced memory impairment in triple-transgenic Alzheimer’s disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging. 2014. 35(8). 1821-1832. doi: 10.1016/j.neurobiolaging.2014.02.010.

9. Ho A.J., Raji C.A., Becker J.T. et al. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol. Aging. 2010. 31(8). 1326-1339. doi: 10.1016/j.neurobiolaging.2010.04.006.

10. Xu W.L., Atti A.R., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology. 2011. 76(18). 1568-1574. doi: 10.1212/WNL.0b013e3182190d09.

11. Profenno L.A., Porsteinsson A.P., Faraone S.V. Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry. 2010. 67(6). 505-512. doi: 10.1016/j.biopsych.2009.02.013.

12. Gustafson D., Rothenberg E., Blennow K., Steen B., Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 2003. 163(13). 1524-8. doi: 10.1001/archinte.163.13.1524.

13. Luchsinger J.A., Cheng D., Tang M.X., Schupf N., Mayeux R. Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer. Dis. Assoc. Disord. 2012. 26(2). 101-105. doi: 10.1097/WAD.0b013e318222f0d4.

14. Wotton C.J., Goldacre M.J. Age at obesity and association with subsequent dementia: Record linkage study. Postgrad. Med. J. 2014. 90(1068). 547-51. doi: 10.1136/postgradmedj-2014-132571.

15. Moser V.A., Pike C.J. Obesity and sex interact in the regulation of Alzheimer’s disease. Neurosci. Biobehav. Rev. 2016. 67. 102-118. doi: 10.1016/j.neubiorev.2015.08.021.

16. Singh-Manoux A., Dugravot A., Shipley M. et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. Alzheimer’s Dement. 2018. 14(2). 178-186. doi: 10.1016/j.jalz.2017.06.2637.

17. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O’Meara E.S., Longstreth W.T., Jr. et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009. 66(3). 336-342. doi: 10.1001/archneurol.2008.582.

18. Anstey K.J., Cherbuin N., Budge M., Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes. Rev. 2011. 12(5). e426-e437. doi: 10.1111/j.1467-789X.2010.00825.x.

19. Lee C.M., Woodward M., Batty G.D. et al. Association of anthropometry and weight change with risk of dementia and its major subtypes: A meta-analysis consisting 2.8 million adults with 57 294 cases of dementia. Obes. Rev. 2020. doi: 10.1111/obr.12989.

20. Li X.Y., Zhang M., Xu W. et al. Midlife modifiable risk factors for dementia: a systematic review and meta-analysis of 34 prospective cohort studies. Curr. Alzheimer. Res. 2019. 16(14). 1254-1268. doi: 10.2174/1567205017666200103111253.

21. Borshchev Y.Y., Uspensky Y.P., Galagudza M.M. Pathogenetic pathways of cognitive dysfunction and dementia in metabolic syndrome. Life Sci. 2019. 237. 116932. doi: 10.1016/j.lfs.2019.116932.

22. Silva M.V.F., Loures C.M.G., Alves L.C.V., de Souza L.C., Borges K.B.G., Carvalho M.D.G. Alzheimer’s disease: risk factors and potentially protective measures. J. Biomed. Sci. 2019. 26(1). 33. doi: 10.1186/s12929-019-0524-y.

23. Folch J., Olloquequi J., Ettcheto M. et al. The involvement of peripheral and brain insulin resistance in late onset Alzheimer’s dementia. Front. Aging Neurosci. 2019. 11. 236. Published 2019 Sep 6. doi: 10.3389/fnagi.2019.00236.

24. Pashkovska N.V., Pankiv V.I., Grinko N.V., Pashkovska O.V. Diabetes mellitus and Alzheimer’s disease. Mìžnarodnij endokrinologìčnij žurnal. 2019. 15(3). 188-195. doi: 10.22141/2224-0721.15.3.2019.172103.

25. Gudala K., Bansal D., Schifano F., Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J. Diabetes Investig. 2013. 4(6). 640-50. doi: 10.1111/jdi.12087.

26. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999. 53(9). 1937-42. doi: 10.1212/wnl.53.9.1937.

27. Cheng G., Huang C., Deng H., Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern. Med. J. 2012. 42(5). 484-91. doi: 10.1111/j.1445-5994.2012.02758.x.

28. Dodd G.T., Tiganis T. Insulin action in the brain: Roles in energy and glucose homeostasis. J. Neuroendocrinol. 2017. 29(10). doi: 10.1111/jne.12513.

29. Costello D.A., Claret M., Al-Qassab H. et al. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One. 2012. 7(2). e31124. doi: 10.1371/journal.pone.0031124.

30. Crane P.K., Walker R., Hubbard R.A. et al. Glucose levels and risk of dementia. N. Engl. J. Med. 2013. 369(6). 540-8. doi: 10.1056/NEJMoa1215740.

31. Laws S.M., Gaskin S., Woodfield A. et al. Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. Sci. Rep. 2017. 7(1). 9766. doi: 10.1038/s41598-017-09577-4.

32. Bernstein L.H. Brain and cognition. Available from: https://pharmaceuticalintelligence.com/2015/10/14/ brain-and-cognition/

33. De la Monte S.M., Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem. Pharmacol. 2014. 88(4). 548-59. doi: 10.1016/j.bcp.2013.12.012.

34. Derakhshan F., Toth C. Insulin and the brain. Curr. Diabetes Rev. 2013. 9(2). 102-16.

35. Shpakov A., Chistyakova O., Derkach K., Bondareva V. Hormonal signaling systems of the brain in diabetes mellitus. In: Chang R.C.C., ed. Neurodegenerative Diseases. Rijeka, Croatia: Intech Open Access Publisher, 2011. 349-386 pp. doi: 10.5772/28930.

36. Kleinridders A., Ferris H.A., Cai W., Kahn C.R. Insulin action in brain regulates systemic metabolism and brain function. Diabetes. 2014. 63(7). 2232-43. doi: 10.2337/ db14-0568.

37. Leszek J., Trypka E., Tarasov V.V., Ashraf G.M., Aliev G. Type 3 diabetes mellitus: a novel implication of Alzheimer’s disease. Curr. Top. Med. Chem. 2017. 17(12). 1331-1335. doi: 10.2174/1568026617666170103163403.

38. Jackson K., Barisone G.A., Diaz E., Jin L.W., DeCarli C., Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann. Neurol. 2013. 74(4). 517-26. doi: 10.1002/ana.23956.

39. Xie L., Helmerhorst E., Taddei K., Plewright B., Van Bronswijk W., Martins R. Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 2002. 22(10). RC221. doi: 10.1523/JNEUROSCI.22-10-j0001.2002.

40. Pivovarova O., Höhn A., Grune T., Pfeiffer A.F., Rudovich N. Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer’s disease? Ann. Med. 2016. 48(8). 614-624. doi: 10.1080/07853890.2016.1197416.

41. Kimura N. Diabetes mellitus induces Alzheimer’s disease pathology: histopathological evidence from animal models. Int. J. Mol. Sci. 2016. 17(4). 503. doi: 10.3390/ijms17040503.

42. Abbatecola A.M., Rizzo M.R., Barbieri M. et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology. 2006. 67(2). 235-40. doi: 10.1212/01.wnl.0000224760.22802.e8.

43. Macauley S.L., Stanley M., Caesar E., Yamada S., Raichle M., Perez R. et al. Hyperglycemia modulates extracellular amyloid-β levels and neuronal activity in vivo. J. Clin. Invest. 2015. 125. 2463-2467. doi: 10.1172/jci79742.

44. Stanley M., Macauley S.L., Holtzman D.M. Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? J. Exp. Med. 2016. 213(8). 1375-1385. doi: 10.1084/jem.20160493.

45. Ko S.Y., Ko H.A., Chu K.H., Shieh T.M., Chi T.C., Chen H.I., Chang W.C., Chang S.S. The possible mechanism of advanced glycation end products (AGEs) for Alzheimer’s disease. PLoS One. 2015. 10(11). e0143345. doi: 10.1371/journal.pone.0143345.

46. Li X.H., Du L.L., Cheng X.S., Jiang X., Zhang Y., Lv B.L. et al. Glycation exacerbates the neuronal toxicity of beta-amyloid. Cell Death Dis. 2013. 4. e673. doi: 10.1038/cddis.2013.180.

47. Wu J.H., Haan M.N., Liang J., Ghosh D., Gonzalez H.M., Herman W.H. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann. Epidemiol. 2003. 13(5). 369-76.

48. Weinstock R.S., Teresi J., Goland R. et al. Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes: five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study. Diabetes Care. 2011. 34(2). 274-9. doi: 10.2337/dc10-1346.

49. Launer L.J., Miller M.E., Williamson J.D. et al. Effects of randomization to intensive glucose lowering on brain structure and function in type 2 diabetes ACCORD Memory in Diabetes Study. Lancet Neurol. 2011. 10(11). 969-77. doi: 10.1016/S1474-4422(11)70188-0.

50. Feinkohl I., Aung P.P., Keller M. et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014. 37(2). 507-15. doi: 10.2337/dc13-1384.

51. De Galan B.E., Zoungas S., Chalmers J. et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetes Care. 2014. 37(2). 507-15. doi: 10.2337/dc13-1384.

52. Shukla V., Shakya A.K., Perez-Pinzon M.A., Dave K.R. Cerebral ischemic damage in diabetes: an inflammatory perspective. J. Neuroinflammation. 2017. 14(1). 21. doi: 10.1186/s12974-016-0774-5.

53. Roostaei T., Nazeri A., Felsky D. et al. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer’s disease. Mol. Psychiatry. 2017. 22(2). 287-295. doi: 10.1038/mp.2016.35.

54. Zhu H., Xue X., Wang E. et al. Amylin receptor ligands reduce the pathological cascade of Alzheimer’s disease. Neuropharmacology. 2017. 119. 170-181. doi: 10.1016/j.neuropharm.2017.03.030.

55. Moreno-Gonzalez I., Edwards Iii G., Salvadores N., Shahnawaz M., Diaz-Espinoza R., Soto C. Molecular interaction between type 2 diabetes and Alzheimer’s disease through cross-seeding of protein misfolding. Mol. Psychiatry. 2017. 22(9). 1327-1334. doi: 10.1038/mp.2016.230.

56. Jackson K., Barisone G.A., Diaz E., Jin L.W., DeCarli C., Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann. Neurol. 2013. 74(4). 517-26. doi: 10.1002/ana.23956.

57. Zhu H., Stern R., Tao Q. et al. An amylin analog used as a challenge test for Alzheimer’s disease. Alzheimer’s Dement. (NY). 2017. 3(1). 33-43. doi: 10.1016/j. trci.2016.12.002.

58. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L. et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996. 347(9009). 1141-1145. doi: 10.1016/S0140-6736(96)90608-X.

59. Staessen J.A., Richart T., Birkenhager W.H. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension. 2007. 49(3). 389-400. doi: 10.1161/01.HYP.0000258151.00728.d8.

60. Skoog I., Gustafson D. Update on hypertension and Alzheimer’s disease. Neurol. Res. 2006. 28(6). 605-611. doi: 10.1179/016164106X130506.

61. Popp J., Meichsner S., Kolsch H., Lewczuk P., Maier W., Kornhuber J. et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer’s disease. Biochem. Pharmacol. 2013. 86(1). 37-42. doi: 10.1016/j.bcp.2012.12.007.

62. Xue-shan Z., Juan P., Qi W., Zhong R., Li-hong P., Zhi-han T. et al. Imbalanced cholesterol metabolism in Alzheimer’s disease. Clin. Chim. Acta. 2016. 456. 107-114. doi: 10.1016/j.cca.2016.02.024.

63. Ricciarelli R., Canepa E., Marengo B., Marinari U.M., Poli G., Pronzato M.A. et al. Cholesterol and Alzheimer’s disease: a still poorly understood correlation. IUBMB Life. 2012. 64(12). 931-935. doi: 10.1002/iub.1091.

64. Ullrich C., Pirchl M., Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol. Cell. Neurosci. 2010. 45. 408-417. doi: 10.1016/j.mcn.2010.08.001.

65. Hendrie H.C., Hake A., Lane K., Purnell C., Unverzagt F., Smith-Gamble V. et al. Statin use, incident dementia and Alzheimer disease in elderly African Americans. Ethn. Dis. 2015. 25(3). 345-354. doi: 10.18865/ed.25.3.345.

66. Lin F.C., Chuang Y.S., Hsieh H.M., Lee T.C., Chiu K.F., Liu C.K. et al. Early statin use and the progression of Alzheimer disease: a total population-based case-control study. Medicine (Baltimore). 2015. 94(47). e2143. doi: 10.1097/MD.0000000000002143.

67. Song Y., Nie H., Xu Y., Zhang L., Wu Y. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr. Gerontol. Int. 2013. 13(4). 817-824. doi: 10.1111/ggi.12044.

68. McGuinness B., Craig D., Bullock R., Passmore P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. 2016. (1). Cd003160. 10.1002/14651858.CD003160.pub3.

69. Jiang C., Li G., Huang P., Liu Z., Zhao B. The gut microbiota and Alzheimer’s disease. J. Alzheimer’s Dis. 2017. 58(1). 1-15. doi: 10.3233/JAD-161141.

70. Solas M., Milagro F.I., Ramírez M.J., Martínez J.A. Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. Curr. Opin. Pharmacol. 2017. 37. 87-92. doi: 10.1016/j.coph.2017.10.005.

71. Kuehn B.M. In Alzheimer research, glucose metabolism moves to center stage. JAMA. 2020. doi: 10.1001/jama.2019.20939.

Similar articles

Diabetes mellitus and Alzheimer’s disease
Authors: Pashkovska N.V. (1), Pankiv V.I. (2), Grinko N.V. (1), Pashkovska O.V. (3)
1 - Bukovinian State Medical University, Chernivtsi, Ukraine
2 - Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
3 - Charles University in Prague, Prague, the Czech Republic

International journal of endocrinology Том 15, №3, 2019
Date: 2019.07.09
Categories: Endocrinology
Sections: Specialist manual
Cognitive impairment in patients with type 2 diabetes mellitus: the role of hypoglycemic therapy
Authors: Пашковська Н.В.
Вищий державний навчальний заклад України «Буковинський державний медичний університет», м. Чернівці, Україна

International journal of endocrinology Том 14, №1, 2018
Date: 2018.05.04
Categories: Endocrinology
Sections: Specialist manual
Autonomic and cognitive disturbances in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Authors: Ye.S. Sirchak, O.O. Boldizhar, V.I. Griga, O.I. Petrichko
Uzhhorod National University, Uzhhorod, Ukraine

"Gastroenterology" Том 53, №4, 2019
Date: 2019.11.21
Categories: Gastroenterology
Sections: Clinical researches
Perspectives for the use of resveratrol for the treatment of diabetes mellitus and its complications
Authors: Соколова Л.К., Пушкарев В.М.
ГУ «Институт эндокринологии и обмена веществ имени В.П. Комиссаренко НАМН Украины», г. Киев, Украина

International journal of endocrinology Том 14, №8, 2018
Date: 2019.02.11
Categories: Endocrinology
Sections: Specialist manual

Back to issue